# Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

> **NCT02052596** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 935 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes Zoster vaccine GSK 1437173A
- **BIOLOGICAL:** Boostrix

## Key facts

- **NCT ID:** NCT02052596
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-07
- **Primary completion:** 2015-06-16
- **Final completion:** 2016-04-21
- **Target enrollment:** 935 (ACTUAL)
- **Last updated:** 2018-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052596, "Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02052596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*